- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07371338
Phase-1-Studie zur Bewertung der Sicherheit, Wirksamkeit und Pharmakokinetik von IPS101A bei Parkinson-Patienten
Dosis-Eskalation, Single-Center, Open-label Phase-1-Studie zur Bewertung der Sicherheit, Wirksamkeit und Pharmakokinetik des Adeno-assoziierten Virus(AAV)-Gentherapieprodukts IPS101A bei Parkinson-Patienten mit Hoehn-Yahr-Stadium 4-5, diagnostiziert vor mehr als 10 Jahren und unkontrolliert durch alle verfügbaren Monotherapien oder Kombinationstherapien
The purpose of this study is to evaluate the dose-related safety and tolerability of IPS101A, an adeno-associated virus (AAV) gene therapy, in patients with Parkinson's disease who exhibit severe functional impairment corresponding to Hoehn & Yahr stages 4-5 and whose symptoms are not adequately controlled despite all available monotherapy and combination therapy options. In addition, the study aims to assess the maximum tolerated dose (MTD) of IPS101A, as well as its preliminary efficacy and pharmacokinetic (PK) characteristics.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
- Name: ChoLong Park
- Telefonnummer: +82-2-3499-4266
- E-Mail: clpark@innopeutics.com
Studieren Sie die Kontaktsicherung
- Name: Tae-gyun Kim
- E-Mail: contact@innopeutics.com
Studienorte
-
-
-
Seoul, Südkorea
- Rekrutierung
- Severance Hospital
-
Kontakt:
- Professor, MD, PhD
- E-Mail: phlee@yuhs.ac
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Subjects who have a diagnosis of Parkinson's disease that meets the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria at the time of the Screening Visit.
- Male or female subjects aged 50 to 80 years (inclusive) at the time of providing written informed consent, with a documented diagnosis of Parkinson's disease.
- Subjects with a duration of Parkinson's disease of at least 10 years prior to the Screening Visit, based on medical history and/or medical records.
- Subjects with Parkinson's disease that is inadequately controlled despite all available standard-of-care treatments, including monotherapy or combination therapy, as determined by the Investigator.
- Subjects with a Hoehn & Yahr stage of 4 or 5 in the off state at the Screening Visit.
Exclusion Criteria:
- Subjects with Parkinson's disease dementia (PDD) who meet the diagnostic criteria established by the Movement Disorder Society (MDS) Task Force, as determined by the Investigator at Screening.
- Subjects with a Korean Mini-Mental State Examination (K-MMSE) score ≤ 24 at the Screening assessment.
- Subjects in whom imaging findings suggestive of Parkinsonism-plus syndrome are observed on PET and MRI performed at the Screening Visit, as assessed by the Investigator and/or a qualified imaging specialist.
- Subjects who do not meet the diagnostic criteria for Parkinson's disease dementia but present with major visual hallucinations, as judged by the Investigator.
- Subjects with drug-induced parkinsonism, confirmed by clinical history and/or medical records, and determined by the Investigator.
- Subjects who are judged by the investigator to be unsuitable for participation in this clinical trial.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Low dose (1.0 x 10^10 vg/patient)
IPS101A |
The investigational product (IP) will be administered as a single dose. All subjects will receive stereotactic injections into the left and right substantia nigra of the midbrain, with one administration per side. |
|
Experimental: High dose(2.0 x 10^10 vg/patient)
IPS101A |
The investigational product (IP) will be administered as a single dose. All subjects will receive stereotactic injections into the left and right substantia nigra of the midbrain, with one administration per side. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Safety Evaluation: dose-limiting toxicity (DLT)
Zeitfenster: Baseline to Week 8
|
Frequency and proportion of subjects who developed dose-limiting toxicity (DLT) |
Baseline to Week 8
|
|
Safety Evaluation: Severity and frequency of reported adverse events
Zeitfenster: Baseline to Week 52
|
Assess severity and frequency of reported adverse events |
Baseline to Week 52
|
|
Safety Evaluation: clinically-relevant changes in laboratory testing assessed by medical personnel
Zeitfenster: Baseline to Week 52
|
The clinical significance of laboratory test results after administration of a clinical trial drug is confirmed by comparing them with those before administration. |
Baseline to Week 52
|
|
Safety Evaluation: clinically-relevant changes in physical exams assessed by medical personnel
Zeitfenster: Baseline to Week 52
|
The results of the physical examination after administration of the clinical trial drug are compared with those before administration to determine whether clinically significant symptoms occur. |
Baseline to Week 52
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change from Baseline in Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores (defined on/off)
Zeitfenster: Baseline to Weeks 4, 12, 24, 36, and 52.
|
Each symptom is rated on a scale of 0 to 4, with higher scores indicating more severe Parkinson's disease. |
Baseline to Weeks 4, 12, 24, 36, and 52.
|
|
Change from Baseline in Hoehn & Yahr stage (defined on/off)
Zeitfenster: Weeks 1, 4, 12, 24, 36, and 52.
|
This scale is classified from 0 to 5, with a higher score indicating a more severe degree of Parkinson's disease. |
Weeks 1, 4, 12, 24, 36, and 52.
|
|
Change from Baseline in Non-Motor Symptoms Scale for Parkinson's Disease (NMSS)
Zeitfenster: Weeks 4, 12, 24, 36, and 52.
|
This scale is rated on a scale of severity (0-3 points) and frequency (1-4 points). A higher score indicates more severe Parkinson's disease. |
Weeks 4, 12, 24, 36, and 52.
|
|
Change from Baseline in Parkinson's Disease Questionnaire (PDQ-39) scores
Zeitfenster: Weeks 4, 12, 24, 36, and 52
|
The scale consists of 800 points, and a higher score indicates a lower quality of life. |
Weeks 4, 12, 24, 36, and 52
|
|
Distribution evaluation of IPS101A (AAV9 vector distribution evaluation)-CSF
Zeitfenster: Baseline to Week 52
|
After IP administration, the detection of AAV genome was measured using q-PCR. |
Baseline to Week 52
|
|
Distribution evaluation of IPS101A (AAV9 vector distribution evaluation)-blood
Zeitfenster: Baseline to Week 52
|
After IP administration, the detection of AAV genome was measured using q-PCR. |
Baseline to Week 52
|
|
Evaluation of humoral (anti-AAV9 antibodies) and cellular (IFN-γ activity) immune responses to AAV9
Zeitfenster: Baseline to Week 52
|
After IP administration, the detection of AAV genome was measured using ELISA |
Baseline to Week 52
|
|
Assessment of AAV9 shedding in biological specimens-urine
Zeitfenster: Baseline to Week 52
|
After IP administration, the detection of AAV genome was measured using q-PCR. |
Baseline to Week 52
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- IPS101A-10
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .